文献速递MDS 与骨髓增殖性肿瘤血栓与止血

基因组时代评估原发性血小板增多症患者的血栓风险

Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.
PubMed 文献 · Leukemia · 2017-05-22

本文综述了原发性血小板增多症(ET)中驱动突变(JAK2V617F、CALR、MPL)及非驱动突变与血栓风险的相关证据。JAK2V617F 似为风险修饰性突变,多项研究显示其增加血栓事件可能性,已被纳入预后模型并可能影响治疗决策;CALR 和 MPL 突变与血管事件关联较不明确。

要点

  • JAK2V617F 似为风险修饰性突变,研究显示其增加 ET 患者血栓事件可能性。
  • JAK2V617F 已被纳入预后模型,其存在可能影响治疗决策。
  • CALR 和 MPL 突变与血管事件发生的关联较不明确。

核心结论

  • JAK2V617F 似为风险修饰性突变,已被纳入预后模型并可能影响治疗决策。
  • CALR 和 MPL 突变与血管事件发生的关联较不明确,非驱动突变对血栓风险贡献的信息更为有限。

研究设计与样本

  • 本文为综述,讨论复发性突变在 ET 患者血栓并发症风险中的作用及其在现代预后评分中的权重。

主要发现

  • 大多数 ET 患者可识别出 JAK2V617F、CALR 或 MPL 基因突变等驱动病变。
  • 每种突变与不同临床特征相关,可能调节临床病程、包括血管事件在内的并发症风险及生存。
  • JAK2V617F 似为风险修饰性突变,多项研究显示其增加 ET 患者血栓事件的可能性。
  • CALR 和 MPL 突变与血管事件发生的关联较不明确。
  • 关于额外非驱动病变对血栓风险贡献的信息更为有限。

关键数值与推荐

  • JAK2V617F 已被纳入预后模型,其存在可能影响治疗决策。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The molecular characterization of myeloproliferative neoplasms, including essential thrombocythemia (ET), has enabled deeper understanding of their pathogenesis. A driver lesion, namely, Janus kinase (JAK)2V617F, calreticulin (CALR) or myeloproliferative leukemia (MPL) gene mutation can be identified in the vast majority of patients. Each of these mutations is associated with distinct clinical features and may modulate the patients' clinical course, risk of complications, including vascular events, and survival. JAK2V617F appears to be a risk-modifying mutation and has been shown to increase the likelihood of thrombotic events in patients with ET across studies. As such, it has been included in prognostic models and its presence may influence treatment decisions. The association of CALR and MPL mutations with the incidence of vascular events has been less clear. Even more limited information is available on the contribution of additional non-driver lesions to the thrombotic risk. In this review we discuss the available evidence on the role of recurrent mutations in the risk of thrombotic complications in patients with ET and how these mutations weigh into modern prognostic scores.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Falchi L, Kantarjian HM, Verstovsek S, et al. Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era. Leukemia. 2017. PMID: 28529308. doi:10.1038/leu.2017.150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。